Cetera Investment Advisers
RXRX icon

Cetera Investment Advisers’s Recursion Pharmaceuticals RXRX Stock Holding History

Cetera Investment Advisers’s Portfolio RXRX Stock Details RXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$16 Buy
+100
New +$386 ﹤0.01% 4790

Other funds holding RXRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
SoftBank Group
SoftBank Group Tokyo, Japan $11.4B AUM 27.91% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
MCMU
MIC Capital Management (UK) London, United Kingdom $352M AUM 0.23% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Cetera Investment Advisers's RXRX Position: Q1 2026 in Review

Cetera Investment Advisers reduced its Recursion Pharmaceuticals (RXRX) stake by 1% in Q1 2026, selling an estimated $5.06K and leaving 127,695 shares worth $392K. The position accounts for ﹤0.01% of the portfolio, ranked #3738.

Cetera Investment Advisers first reported a position in RXRX in Q4 2023 and has held it in 10 quarters since. The position peaked at $622K in Q3 2025. 335 funds tracked by Wall St. Rank hold RXRX as of Q1 2026.

  • Cetera Investment Advisers held 127,695 shares of Recursion Pharmaceuticals worth $392K as of Q1 2026.
  • Cetera Investment Advisers sold 1,309 Recursion Pharmaceuticals shares in Q1 2026, an estimated $5.06K.
  • Recursion Pharmaceuticals made up ﹤0.01% of Cetera Investment Advisers's portfolio in Q1 2026, its #3738 holding.
  • Cetera Investment Advisers first reported a position in Recursion Pharmaceuticals in Q4 2023 and has held it in 10 quarters since.
  • Cetera Investment Advisers's Recursion Pharmaceuticals position peaked at $622K in Q3 2025.
  • 335 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q1 2026.

Based on Cetera Investment Advisers's 13F filing for Q1 2026, filed 13 May 2026.